CClinicalTrials.gg
Sign In
CompletedNCT00501423ADRIEUpdated Jan 31, 2014

Antiplatelet Drug Resistances and Ischemic Events

An observational study in Symptomatic Atherothrombosis, sponsored by Pierre Fontana. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-01-31.

Sponsored by Pierre Fontana · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
771
Ages
18 Years and older
Sex
All
01

Study summary

The ADRIE study is an observational study on the clinical relevance of platelet reactivity in aspirin and clopidogrel treated cardiovascular patients.

Read the detailed description

The ADRIE study is an observational study on the clinical relevance of platelet reactivity in aspirin and clopidogrel treated cardiovascular patients.

Main objective:

  • to determine if platelet reactivity, assessed by specific and non-specific tests, is predictive of ischemic events during the 3-year follow-up.

Secondary objectives:

  • primary outcome in each pre-specified sub-group : patients with coronary artery disease, ischemic stroke or peripheral arterial disease as main qualifying disease at entry,
  • to determine if platelet reactivity, assessed by specific and non-specific tests, is predictive of bleeding events during the 3-year follow-up,
  • to investigate potential determinants of platelet reactivity at entry in the study
02

Conditions studied

  • Symptomatic Atherothrombosis

Browse trials for

Keywords

  • antiplatelet drug
  • resistance
  • atherothrombosis
03

In context

Thrombosis

1,508 studies on the registry are indexed under Thrombosis; 239 are open to participants now.

This study's enrollment of 771 is above the median of 213 across 588 observational studies indexed under Thrombosis.

Browse Thrombosis studies →

Lead sponsor

Pierre Fontana is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Documented symptomatic ischemic atherothrombotic disease

Inclusion criteria

  • Documented symptomatic ischemic atherothrombotic disease treated by aspirin, clopidogrel or both.

Exclusion criteria

Exclusion Criteria:

  • Known platelet disorder
  • Chronic treatment by antiplatelet drugs other than aspirin or clopidogrel.
  • Chronic anticoagulant treatment
  • Chronic non steroid anti inflammatory drug treatment
  • Active cancer
  • Ongoing aspirin or clopidogrel treatment taken for more than 5 years prior to inclusion
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
771 participants (actual)
06

What researchers measure

Primary outcomes

  1. MACE

    adjudicating committee

    Time frame: prospective follow-up

Secondary outcomes

  1. MACE in pre-specified sub-groups

    patients with coronary artery disease, ischemic stroke or peripheral arterial disease as main qualifying disease at entry

    Time frame: prospective follow-up

Other outcomes

  1. potential determinants of platelet reactivity

    Time frame: at inclusion

07

Study locations

1 site
  • University Hospital Geneva; Beziers and Monpellier University Hospitals, France
    Geneva - Beziers - Montpellier, France
08

References and documents

Publications

  • Reny JL, Berdague P, Poncet A, Barazer I, Nolli S, Fabbro-Peray P, Schved JF, Bounameaux H, Mach F, de Moerloose P, Fontana P; Antiplatelet Drug Resistances and Ischemic Events (ADRIE) Study Group. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation. 2012 Jun 26;125(25):3201-10. doi: 10.1161/CIRCULATIONAHA.111.085464. Epub 2012 May 21. PubMed 22615340 ↗
  • Fontana P, James R, Barazer I, Berdague P, Schved JF, Rebsamen M, Vuilleumier N, Reny JL. Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study. J Thromb Haemost. 2011 Aug;9(8):1664-6. doi: 10.1111/j.1538-7836.2011.04409.x. No abstract available. PubMed 21692977 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 31, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00501423
Lead sponsor
Pierre Fontana
Collaborators
Beziers Hospital, University Hospital, Montpellier, Ministry of Health, France, Swiss National Science Foundation
Responsible party
Pierre Fontana (PI, University Hospital, Geneva) — Sponsor-investigator
First posted
Jul 16, 2007
Start date
Jun 2006
Primary completion
Sep 2010
Completion
Sep 2010
Last update
Jan 31, 2014

Study contacts

Pierre Fontana, MD PhD
principal investigator · University Hospitals Geneva, Switzerland
Jean-Luc Reny, MD PhD
principal investigator · Beziers Hospital, France

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Thrombosis→

Other studies from this sponsor

Pierre Fontana

Start the discussion